Comparative Pharmacology
Head-to-head clinical analysis: AMPHOTERICIN B versus M ZOLE 3 COMBINATION PACK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPHOTERICIN B versus M ZOLE 3 COMBINATION PACK.
AMPHOTERICIN B vs M-ZOLE 3 COMBINATION PACK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to ergosterol in fungal cell membranes, forming pores that increase permeability and cause leakage of intracellular contents, leading to cell death.
Miconazole inhibits fungal CYP450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity. Zinc pyrithione inhibits fungal growth by disrupting membrane transport and inhibiting energy metabolism.
0.5-1.5 mg/kg/day IV over 2-6 hours; for invasive aspergillosis, 1 mg/kg/day; for cryptococcal meningitis, 0.7 mg/kg/day IV in combination with flucytosine; liposomal formulation: 3-5 mg/kg/day IV. Maximum dose: 1.5 mg/kg/day for conventional amphotericin B deoxycholate.
A single oral dose of 3 tablets (M-ZOLE 3 COMBINATION PACK) as a one-time treatment.
None Documented
None Documented
Clinical Note
moderateAmphotericin B + Digoxin
"The risk or severity of adverse effects can be increased when Amphotericin B is combined with Digoxin."
Clinical Note
moderateAmphotericin B + Digitoxin
"The risk or severity of adverse effects can be increased when Amphotericin B is combined with Digitoxin."
Clinical Note
moderateAmphotericin B + Deslanoside
"The risk or severity of adverse effects can be increased when Amphotericin B is combined with Deslanoside."
Clinical Note
moderateTerminal half-life: 24–48 hours initially, prolonged to 15 days with repeated dosing due to tissue redistribution.
Terminal elimination half-life 20-30 hours in healthy adults; prolonged in renal impairment (up to 40-50 hours) and hepatic impairment
Renal: ~2-5% unchanged; biliary/fecal: ~40% as metabolites; extensive tissue binding delays excretion.
Renal: ~70-80% as unchanged drug and metabolites; biliary/fecal: ~20%
Category C
Category C
Antifungal
Antifungal
Amphotericin B + Acetyldigitoxin
"The risk or severity of adverse effects can be increased when Amphotericin B is combined with Acetyldigitoxin."